Practical aspects of chimeric antigen receptor T-cell administration: From commercial to point-of-care manufacturing

Chimeric antigen receptor T-cells targeting the CD19 antigen have achieved impressive results in patients with relapsed/refractory (R/R) B-cell malignancies, leading to Outdoor Seating Set their approval in the European Union and other jurisdictions.In Spain, the 100% academic anti-CD19 CART-cell product varnimcabtagene autoleucel (var-cel, ARI-000

read more